Stay updated on Immunotherapy with Chemo in HER2-neg IBC Clinical Trial
Sign up to get notified when there's something new on the Immunotherapy with Chemo in HER2-neg IBC Clinical Trial page.

Latest updates to the Immunotherapy with Chemo in HER2-neg IBC Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedThe page’s displayed software/version revision label was updated from v3.5.2 to v3.5.3.SummaryDifference0.0%

- Check24 days agoChange DetectedPage revision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check38 days agoChange Detected- Added a new reference term 'Inflammatory breast carcinoma' and a Resources entry for the Genetic and Rare Diseases Information Center. - Added iRECIST guideline citation (Lancet Oncol. 2017) to the study references and removed the corresponding Erratum (Lancet Oncol. 2019).SummaryDifference0.2%

- Check53 days agoChange DetectedRevision: v3.5.0 added; Revision: v3.4.3 removed.SummaryDifference0.0%

- Check60 days agoChange DetectedPage revision updated from v3.4.2 to v3.4.3.SummaryDifference0.0%

- Check67 days agoChange DetectedAddition and deletion of the same iRECIST reference cancel each other out, resulting in no net change to the page content. The study's design and outcome information remain unchanged.SummaryDifference0.0%

Stay in the know with updates to Immunotherapy with Chemo in HER2-neg IBC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Immunotherapy with Chemo in HER2-neg IBC Clinical Trial page.